Company intelligence / Profile preview

Beacon Biotechnology

London, United Kingdom

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Beacon Therapeutics is a clinical-stage gene therapy company focused on developing next-generation treatments for retinal diseases. Launched in 2023 with significant backing from Syncona and Forbion, the company’s lead program, AGTC-501, is currently in late-stage clinical trials for X-linked retinitis pigmentosa (XLRP). Beacon’s portfolio also includes several preclinical programs targeting dry age-related macular degeneration and cone-rod dystrophy. The company leverages a proprietary AAV-based platform to deliver functional copies of genes to the retina, aiming to preserve or restore vision in patients with high unmet needs.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Beacon Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beacon Biotechnology.

Explore the full profile